


**Product Name** : LDN193189  
**Cat. No.** : PC-42884  
**CAS No.** : 1062368-24-4  
**Molecular Formula** : C<sub>25</sub>H<sub>22</sub>N<sub>6</sub>  
**Molecular Weight** : 406.4824  
**Target** : Anaplastic Lymphoma Kinase (ALK)  
**Solubility** :



### Biological Activity

LDN193189 (DM 3189) is a potent, selective **BMP type I receptor** that inhibits BMP4-induced phosphorylation of SMAD1/5/8 with IC<sub>50</sub> of 5 nM, displays >200-fold selectivity for BMP signaling over TGF-β signaling (IC<sub>50</sub>>1,000 nM). LDN193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 (IC<sub>50</sub>=5 nM and 30 nM, respectively), with weaker effects on activin and the TGF-β type I receptors ALK4, ALK5 and ALK7. LDN193189 also blocks the transcriptional activity induced by either constitutively active ALK2 R206H or ALK2 Q207D mutant proteins. LDN193189 affects BMP-induced osteoblast differentiation, attenuates ectopic ossification in vivo.

### References

- Yu PB, et al. *Nat Med*. 2008 Dec;14(12):1363-9.  
Cuny GD, et al. *Bioorg Med Chem Lett*. 2008 Aug 1;18(15):4388-92.  
Cannon JE, et al. *Br J Pharmacol*. 2010 Sep;161(1):140-9.  
Steinbicker AU, et al. *Blood*. 2011 May 5;117(18):4915-23.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com